<code id='3339DBFD73'></code><style id='3339DBFD73'></style>
    • <acronym id='3339DBFD73'></acronym>
      <center id='3339DBFD73'><center id='3339DBFD73'><tfoot id='3339DBFD73'></tfoot></center><abbr id='3339DBFD73'><dir id='3339DBFD73'><tfoot id='3339DBFD73'></tfoot><noframes id='3339DBFD73'>

    • <optgroup id='3339DBFD73'><strike id='3339DBFD73'><sup id='3339DBFD73'></sup></strike><code id='3339DBFD73'></code></optgroup>
        1. <b id='3339DBFD73'><label id='3339DBFD73'><select id='3339DBFD73'><dt id='3339DBFD73'><span id='3339DBFD73'></span></dt></select></label></b><u id='3339DBFD73'></u>
          <i id='3339DBFD73'><strike id='3339DBFD73'><tt id='3339DBFD73'><pre id='3339DBFD73'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:hotspot    Page View:18126
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In